YMAB — Y-mAbs Therapeutics Balance Sheet
0.000.00%
- $199.67m
- $132.44m
- $87.69m
Annual balance sheet for Y-mAbs Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 115 | 182 | 106 | 78.6 | 67.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 7.71 | 12.5 | 22.5 | 19.7 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 122 | 202 | 130 | 111 | 98.5 |
Net Property, Plant And Equipment | 6.39 | 5.69 | 2.34 | 1.64 | 0.859 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 132 | 213 | 141 | 128 | 120 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 19.5 | 27.9 | 28.3 | 20.1 | 23.7 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 26.2 | 32.7 | 32.2 | 26.9 | 27.9 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 106 | 180 | 109 | 101 | 92 |
Total Liabilities & Shareholders' Equity | 132 | 213 | 141 | 128 | 120 |
Total Common Shares Outstanding |